首页> 外文期刊>Drug development and industrial pharmacy >Combination of β-cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: Novel technique
【24h】

Combination of β-cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: Novel technique

机译:β-环糊精包合物与自微乳化给药系统的组合,可提高甲氨蝶呤的光稳定性和口服生物利用度:新技术

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In the present study, we prepared an inclusion complex of methotrexate (MTX) with β-cyclodextrin (β-CD) in order to decrease its photosensitivity and enhance its aqueous solubility. Then we incorporated this inclusion complex in a self-microemulsifying drug delivery system (SMEDDS) overall to increase its oral bioavailability. The inclusion complex has been prepared by freeze drying method and characterized by differential scanning calorimetry (DSC), ultraviolet (UV), and infrared (IR) spectroscopy assays. The proper molecular ratio of MTX/β-CD was found to be of 1:7, and the water-solubility of MTX was increased in an average of 10-fold. The photostability studies showed that the MTX became stable on exposure to light. Construction of pseudoternary diagrams were investigated to prepare a MTX/β-CD inclusion complex loaded SMEDDS which was characterized by measuring the particle size and the zeta-potential. The optimum formulation of SMEDDS was a system consisting of ethyl oleate, tween 80, and propylene glycol with a mean droplet size of 39.42nm. In vitro drug release in different pH media showed that the release profile of MTX from the MTX/β-CD loaded SMEDDS was influenced by the pH of the release medium and presented the characteristics of a sustained release profile. Finally, in-vivo studies showed an enhancement of the bioavailability of MTX from the MTX/β-CD loaded SMEDDS form of 1.57-fold. We concluded that the β-CD inclusion complex loaded SMEDDS improved the chemical and physiological properties of MTX and could be a promising means for the delivery of MTX and other unstable and lipophilic drugs by oral route.
机译:在本研究中,我们制备了甲氨蝶呤(MTX)与β-环糊精(β-CD)的包合物,以降低其光敏性并增强其水溶性。然后,我们将此包裹体复合物整体纳入了自微乳化药物递送系统(SMEDDS)中,以提高其口服生物利用度。通过冷冻干燥法制备了包合物,并通过差示扫描量热法(DSC),紫外(UV)和红外(IR)光谱法进行了表征。发现MTX /β-CD的适当分子比为1:7,并且MTX的水溶性平均增加10倍。光稳定性研究表明,MTX在暴露于光线下变得稳定。研究了伪三元图的构建,以制备载有MTX /β-CD包合物的SMEDDS,该SMEDDS通过测量粒径和Zeta电位进行表征。 SMEDDS的最佳配方是由油酸乙酯,吐温80和丙二醇组成的系统,平均液滴尺寸为39.42nm。在不同pH介质中的体外药物释放表明,MTX从负载MTX /β-CD的SMEDDS的释放曲线受释放介质pH的影响,并呈现出持续释放曲线的特征。最后,体内研究表明,MTX /β-CD负载的SMEDDS形式使MTX的生物利用度提高了1.57倍。我们得出的结论是,载有β-CD包合物的SMEDDS改善了MTX的化学和生理特性,可能是通过口服途径传递MTX和其他不稳定和亲脂性药物的有前途的手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号